PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
September 16, 20250 citations

Biomarker Analysis of CD8+ T-Cells in Advanced Urothelial Cancer Treatment Dynamics

Supplementary Figure S9 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study

View Full Paper
Ask AI
Bookmark
Share

Authors

CSChantal F. StockemThe Netherlands Cancer InstituteAGAlberto Gil-JimenezOncode InstituteHAHamza AliEast Carolina University

Discussion

Loading...

Member takes

Overview

Observational analysis reveals CD8+ T-cell dynamics in locally advanced urothelial cancer, highlighting treatment responses to ipilimumab and nivolumab.

Key Points

  • On-treatment analysis indicates changes in CD8+ T-cell populations responding to treatment.
  • Multiplex immunofluorescence was used to assess T-cell dynamics in bladder tissue samples from two responders.
  • Phase IB NABUCCO study provides insight into the effectiveness of ipilimumab combined with nivolumab.
  • Single-cell RNA-sequencing further characterizes the therapeutic response and dynamics of specific T-cell subtypes.

Cite This Study

Stockem et al. (2025) studied this question.

synapsesocial.com/papers/68d4538731b076d99fa589e9https://doi.org/10.1158/1078-0432.30125701
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S8 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study2025
  2. 2Data from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study2025
  3. 3Supplementary Figure S4 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study2025
  4. 4Supplementary Figure S7 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study2025
  5. 5Supplementary Figure S3 from Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study2025